- Home
- CLPR vs PLRX Comparison
CLPR vs PLRX Comparison
Compare CLPR & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | PLRX |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.2M | 61.1M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CLPR | PLRX |
|---|---|---|
| Price | $3.15 | $0.90 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 40.9K | ★ 373.0K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 11.91% | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,997,000.00 | N/A |
| Revenue This Year | $0.91 | N/A |
| Revenue Next Year | $2.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.82 | N/A |
| 52 Week Low | $2.69 | $0.88 |
| 52 Week High | $4.32 | $1.95 |
Technical Indicators
Market Signals| Indicator | CLPR | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 33.98 |
| Support Level | $3.03 | N/A |
| Resistance Level | $3.17 | $1.37 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 35.00 | 6.01 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.